People: Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)
22 Jul 2019
Mr. John Tilton is a Chief Commercial Officer, Rare and Orphan Diseases of Biohaven Pharmaceutical Holding Company Limited. Mr. Tilton has served as our chief commercial officer, rare and orphan diseases since April 2019 and, prior to that, as our chief commercial officer since April 2016. Prior to this, from November 2006 to March 2016, he served in increasingly senior marketing and business roles with Alexion Pharmaceuticals, Inc., including serving as its executive director, global sales and marketing operations from January 2011 to March 2016. Prior to his time at Alexion Pharmaceuticals, Mr. Tilton served as a director, division operations at Pfizer from August 2005 to November 2006, as a regional sales manager for Agouron Pharmaceuticals from November 1999 to August 2005 and as division manager at Sanofi from 1993 to 1999. Mr. Tilton received his BSBA in finance from the University of South Carolina—Columbia.
|Total Annual Compensation, USD||1,506,820|
|Restricted Stock Award, USD||--|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||18,849|
|Fiscal Year Total, USD||1,525,670|